Trial · NCT02100930

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

NCT02100930, Not applicable, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2020-02-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma. Trials, record NCT02100930. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02100930

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
NCT number: NCT02100930
Status: Completed
Phases: Not applicable
Enrollment: 69 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Neuroblastoma
Interventions: Anti-GD2 3F8 Monoclonal Antibody, GM-CSF (granulocyte-macrophage colony-stimulating factor), oral isotretinoin
First posted: 2014-04-01
Last updated: 2020-02-28
Results first posted: 2020-02-28

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Therapeutic Response	2 years	Disease status is defined by the International Neuroblastoma Response Criteria - Complete response/remission (CR): NED; Partial response/remission: \>50% decrease in all disease parameters, exceptbone scan unchanged or improved; no more than 1 positive bone marrow site; Stable disease: \<50% decrease in all tumor markers; Progressive disease (PD): new lesion, or \>25 % increase in any disease marker.
Primary	Complete Remission	2 years	Disease status is defined by the International Neuroblastoma Response Criteria - Complete response/remission (CR): NED; Partial response/remission: \>50% decrease in all disease parameters, exceptbone scan unchanged or improved; no more than 1 positive bone marrow site; Stable disease: \<50% decrease in all tumor markers; Progressive disease (PD): new lesion, or \>25 % increase in any disease marker.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Therapeutic Response	2 years		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Complete Remission	2 years		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Therapeutic Response	Neuroblastoma	No Evidence of Disease	40	Participants
Therapeutic Response	Neuroblastoma	Complete Response	3	Participants
Therapeutic Response	Neuroblastoma	Partial Response	1	Participants
Therapeutic Response	Neuroblastoma	Stable Disease	6	Participants
Therapeutic Response	Neuroblastoma	Progression of Disease	19	Participants
Complete Remission	Neuroblastoma	No Evidence of Disease	40	Participants
Complete Remission	Neuroblastoma	Complete Response	3	Participants
Complete Remission	Neuroblastoma	Partial Response	1	Participants
Complete Remission	Neuroblastoma	Stable Disease	6	Participants
Complete Remission	Neuroblastoma	Progression of Disease	19	Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Neuroblastoma	69
Overall Study	COMPLETED	Neuroblastoma	69
Overall Study	NOT COMPLETED	Neuroblastoma	0

Source ClinicalTrials.gov

Adverse events58

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Edema face	General disorders	Neuroblastoma	6	69
other	Pain	General disorders	Neuroblastoma	6	69
other	Pruritus	Skin and subcutaneous tissue disorders	Neuroblastoma	6	69
other	Urticaria	Skin and subcutaneous tissue disorders	Neuroblastoma	6	69
other	Abdominal pain	Gastrointestinal disorders	Neuroblastoma	5	69
other	Flushing	Vascular disorders	Neuroblastoma	5	69
other	Pain in extremity	Musculoskeletal and connective tissue disorders	Neuroblastoma	5	69
other	Vomiting	Gastrointestinal disorders	Neuroblastoma	5	69
other	Agitation	Psychiatric disorders	Neuroblastoma	4	69
other	Hypotension	Vascular disorders	Neuroblastoma	4	69

1 to 10 of 58Source ClinicalTrials.gov

See all 58 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Neuroblastoma	16	69
Total, other adverse events	Neuroblastoma	69	69
Total, serious adverse events	Neuroblastoma	26	69

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02100930

GET https://conductscience.org/api/trials/v1/NCT02100930/events?page=2

API reference For AI assistants